| OncoTherad® (MRB-CFI-1) Nanoimmunotherapy: A Promising Strategy to Treat Bacillus Calmette–Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer … JCC Alonso, BR de Souza, IB Reis, GC de Arruda Camargo, G de Oliveira, ... International Journal of Molecular Sciences 24 (24), 17535, 2023 | 2 | 2023 |
| A novel therapeutic strategy for non-muscle invasive bladder cancer: OncoTherad® immunotherapy associated with platelet-rich plasma BR de Souza, IB Reis, GC de Arruda Camargo, G Oliveira, QC Dias, ... International Immunopharmacology 123, 110723, 2023 | 2 | 2023 |
| Clinical implications of T-Cells CX3CR1+, Toll-like Receptor 4 signaling pathway, and immune checkpoints in Non-Muscle Invasive Bladder Cancer JCC Alonso, BR de Souza, GC de Arruda Camargo, G de Oliveira, ... Brazilian Journal of Health Review 6 (2), 8301-8313, 2023 | 1 | 2023 |
| A potential new therapeutic option for the treatment of nonmuscle invasive bladder cancer: Combination of intravesical oncotherad immunotherapy and platelet rich plasma (PRP). BRS Sasaki, GCA Camargo, IB Reis, QC Dias, N Duran, WJ Fávaro Journal of Clinical Oncology 39 (6_suppl), 461-461, 2021 | 1 | 2021 |
| Antitumor mechanisms of OncoTherad (MRB-CFI-1) nanoimmunotherapy involving monoamine oxidases: Clinical implications in BCG-unresponsive non-muscle invasive bladder cancer. WJ Fávaro, GCA Camargo, G Oliveira, M Ávila, IM Roberto, JCC Alonso Journal of Clinical Oncology 42 (16_suppl), e14597-e14597, 2024 | | 2024 |
| Relevance of immune tumor microenvironment and its interaction with HABP4 and SERBP1 proteins in bladder cancer. WJ Fávaro, GCA Camargo, G Oliveira, IM Roberto, M Ávila, ADS Santos, ... Journal of Clinical Oncology 42 (16_suppl), e15187-e15187, 2024 | | 2024 |
| Monoamine oxidase as a potential target for the development of new therapeutic strategies for bladder cancer. GCA Camargo, G Oliveira, JCC Alonso, B Ribeiro de Souza, ... Journal of Clinical Oncology 41 (16_suppl), e16611-e16611, 2023 | | 2023 |
| OncoTherad immunotherapy plus platelet rich plasma as potential therapeutic strategy for ovarian cancer: The role of toll-like receptors 2 and 4 signaling pathways. G Oliveira, B Ribeiro de Souza, J Lima Baggio de Paula, ... Journal of Clinical Oncology 41 (16_suppl), e17602-e17602, 2023 | | 2023 |
| New therapeutic approaches for non-muscle invasive bladder cancer (NMIBC): intravesical use of oncotherad biological response modifier and its association with platelet-rich … G Camargo, W Favaro, B Sasaki, I Reis, Q Dias, N Durán Revista dos Trabalhos de Iniciação Científica da UNICAMP, 1-1, 2019 | | 2019 |
